Is It Safe to Use Vasoconstrictors in Association Treated with Amitriptyline or Can It Potentiate Cardiovascular Effects? In Vivo Animal Study

Author(s)

Oliveira, Gabriela Moraes ; Dionisio, Thiago Jose ; Fleury, Camila Assis ; Calvo, Adriana Maria ; Santos, Carlos Ferreira ; Cardoso Faria, Flavio Augusto

• Document type: Journal article
• Source: APPLIED SCIENCES-BASEL; v. 12, n. 23, p. 10-pg., 2022-12-01.

Abstract

Featured Application Cardiovascular safety of vasoconstrictor associated with amitriptyline. This study aimed to evaluate changes in blood pressure of rats treated or not with amitriptyline after infiltration in the buccal sulcus and intravenous injection of epinephrine, felypressin and phenylephrine in equivalent doses (ED) to the amounts present in 2, 8 and 32 local anesthetic tubes. 42 male Wistar rats, with 45-day-old, treated for seven days with amitriptyline hydrochloride (0.3 mg/kg). On the eighth day, the animal was submitted to general anesthesia and surgery for direct blood pressure rate. The significance level was 5%. The treatment with amitriptyline caused a significant decrease in blood pressure of the treated group compared to the control group (101.80 +/- 2.52 and 110.12 +/- 2.91 mmHg, respectively, * p < 0.05), and slightly potentiates the hypertensive response after infiltration of epinephrine (4.11 +/- 0.54; 7.15 +/- 0.55; 9.03 +/- 0.87 mmHg, respectively, 2, 8 and 32 tubes, p > 0.05). Felypressin promotes lower blood pressure changes and phenylephrine proved to be the most potent vasoconstrictor of the three studied, producing important changes in blood pressure and, even though infiltration, in doses greater than 8 tubes (15.43 +/- 1.15; 70.62 +/- 3.70 mmHg, respectively, 8 and 32 tubes, * p < 0.05). The infiltration of the three vasoconstrictors in doses equal to or less than 8 tubes does not cause significant changes in blood pressure, both in the control and amitriptyline treated groups. (AU)

• FAPESP's process: 17/12725-0 - Model of pharmakinetics/pharmacodynamics (PK/PD) on the influence of P450 genetic polymorphism (CYP2C9) of non-steroidal anti-inflammatory drugs and main metabolics from saliva samples through LCMS/MS and its role on prescription personalization
• Grantee: Adriana Maria Calvo
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 15/03965-2 - Role of the renin-angiotensin system in different oral inflammatory models: an experimental interdisciplinary and clinical approach
• Grantee: Carlos Ferreira dos Santos
• Support Opportunities: Research Projects - Thematic Grants